BioSpace News Archive

Medical device incubator and technology brokerage firm, Hatch Medical, L.L.C. announced recently that it has entered into an exclusive brokerage relationship with inventor and CEO, Dr. Robert Ward, MB BS FRCS FRCR and his company, Fixit Medical, Ltd. Hatch Medical will seek to sell or out-license Dr. Ward’s next generation drainage catheter fixation device, Cingo™.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has issued a complete response letter (“CRL”) for its Abbreviated New Drug Application (“ANDA”) for vasopressin. Eagle has now had two conversations with FDA regarding the CRL and will have an additional meeting with FDA

Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced that David Giljohann, CEO, will present at the 2021 BIO CEO & Investor Digital Conference, February 16-18, 2021. The presentation will be available to registered conference attendees for on-demand viewing beginning February 15, 2021 at 9:00AM ET

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that a presentation of clinical study data on its investigational therapy KSI-301 will be made at the upcoming Angiogenesis, Exudation and Degeneration 2021 -

CureVac N.V. (Nasdaq:CVAC) , a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid , announced today the closing of its follow-on public offering of 5,000,000 common shares, at a public offering price of $90.00 per common share, for total gross proceeds of approximately $450 million.

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that it will host a live webinar for the investment community on Tuesday, February 16, 2021 at 1:00 p.m. EST to review clinical data on the company’s investigational AAV-based gene therapies ABO-102 and ABO-101 presented at the 17 th Annual WORLD Symposium ™.

FDA removes clinical hold for pivotal Phase 2 MB-107 clinical trial Company plans to enroll first patient in MB-107 pivotal trial in the second quarter of 2021 Clinical outcomes in investigator-IND XSCID trials continue to show compelling efficacy

First-in-human Phase 1/2 trial in patients with venous malformations (VMs), lymphatic malformations (LMs), and venolymphatic malformations (VLMs) associated with PIK3CA or TEK mutations Clinical trial enrolling patients across multiple sites in the United States

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that a preclinical study in animals demonstrated a potentially significant therapeutic benefit of Annamycin against metastatic osteosarcoma.

THREAD, an innovative technology and service provider that enables decentralized clinical trials (DCTs), and 1nHealth, a digital technology company that works with study sponsors to optimize patient recruitment, today announced a new strategic partnership to enhance recruitment and retention outcomes in DCTs.